Scarica l'app Stockscreener
1.83
3.10%
0.055
Dopo l'orario di chiusura:
1.83
Precedente Chiudi:
$1.775
Aprire:
$1.77
Volume 24 ore:
50,282
Relative Volume:
0.93
Capitalizzazione di mercato:
$3.26M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-4.69%
1M Prestazione:
-8.50%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$1.75
$1.83
Intervallo di 1 settimana:
$1.68
$2.06
Portata 52W:
$1.6313
$2.20
Vivosim Labs Inc Stock (VIVS) Company Profile
Nome
Vivosim Labs Inc
Settore
Industria
Telefono
858-224-1000
Indirizzo
11555 SORRENTO VALLEY ROAD, SAN DIEGO
Confronta VIVS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VIVS
Vivosim Labs Inc
|
1.83 | 3.46M | 0 | 0 | 0 | 0.00 |
|
ONC
Beone Medicines Ltd Adr
|
258.27 | 26.01B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.85 | 114.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3499 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.98 | 6.29B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
484.93 | 63.90B | 14.09B | 4.50B | 2.96B | 39.28 |
Vivosim Labs Inc Stock (VIVS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2018-12-13 | Iniziato | H.C. Wainwright | Buy |
| 2017-11-10 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2017-01-25 | Iniziato | Raymond James | Outperform |
| 2015-08-11 | Downgrade | Cantor Fitzgerald | Buy → Hold |
| 2015-06-29 | Iniziato | Jefferies | Buy |
| 2015-06-29 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Vivosim Labs Inc Borsa (VIVS) Ultime notizie
VivoSim’s NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference - The Globe and Mail
Analytical Overview: VivoSim Labs Inc (VIVS)’s Ratios Tell a Financial Story - DWinneX
VivoSim Labs (VIVS) Unveils NAMkind Platform with Leading Predictive Capabilities | VIVS Stock News - GuruFocus
VivoSim Labs, Inc. Showcases NAMkind™ Platform's Industry-Leading Liver Toxicology Prediction at Digestive Disease Week Conference - Nasdaq
VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference - TradingView
VivoSim Labs regains Nasdaq compliance By Investing.com - Investing.com Nigeria
VivoSim Labs regains Nasdaq compliance - Investing.com
VivoSim Labs Avoids Nasdaq Delisting with Compliance Plan - TipRanks
Organovo Holdings, Inc. Announces Board Appointments - marketscreener.com
Organovo Announces Close Of Sale Of FXR Program To Eli Lilly And Company - marketscreener.com
Organovo: Fiscal Q2 Earnings Snapshot - marketscreener.com
Organovo Holdings, Inc. and BICO Reach Licensing Agreement on Bioprinting Patents - marketscreener.com
VivoSim Labs introduces AI-driven drug testing models By Investing.com - Investing.com Canada
VIVS: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com
Two new option listings and one option delisting on April 24th - TipRanks
VivoSim Announces Emergence from Stealth Mode To Provide Technol - GuruFocus
VivoSim Labs introduces AI-driven drug testing models - Investing.com Australia
VIVS Stock Price and Chart — NASDAQ:VIVS - TradingView
VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market - The Manila Times
VivoSim Labs, Inc. Emerges from Stealth Mode to Revolutionize Drug Discovery with Non-Animal Toxicology Models Following FDA Initiative - Nasdaq
VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from - Bluefield Daily Telegraph
FDA Shift Powers VivoSim's Game-Changing Drug Testing Tech: 50% Cost Reduction Target - Stock Titan
Organovo (ONVO) Rebrands to VivoSim Labs with New Ticker 'VIVS' - GuruFocus
Organovo (ONVO) Rebrands to VivoSim Labs with New Ticker 'VIVS' | ONVO Stock News - GuruFocus
Organovo announces VivoSim to carry forward 3D bioprinting, legacy tech - TipRanks
Organovo rebrands as VivoSim Labs, debuts new ticker - Investing.com
VivoSim to Carry Forward Organovo 3D Bioprinting | ONVO Stock Ne - GuruFocus
Organovo Holdings Announces Transition to VivoSim Labs - TipRanks
VivoSim to Carry Forward Organovo 3D Bioprinting - The Manila Times
Organovo Holdings Inc Name Change To VivoSim Labs Effective April 24, 2025 - TradingView
Strategic Transformation: Organovo Becomes VivoSim Labs to Accelerate 3D Bioprinting Innovation - Stock Titan
Organovo gets upfront payments following sale of its FXR Program to Lilly - Seeking Alpha
Organovo'S FXR Program, Including FXR314, To Be Acquired By Eli Lilly And Company - marketscreener.com
Eli Lilly and Company entered into an asset purchase agreement to acquire FXR Program and Related Assets of Organovo Holdings, Inc. for $60 million. - marketscreener.com
ONVO Stock Quote Price and Forecast - CNN
Organovo Holdings, Inc. Presents FXR314 3D Human Tissue Model Findings - marketscreener.com
ORGANOVO HOLDINGS, INC. : Other Events, Financial Statements and Exhibits (form 8-K) - marketscreener.com
Organovo Holdings, Inc. Announces Executive Changes - marketscreener.com
ONVOOrganovo Holding Latest Stock News & Market Updates - Stock Titan
Imagine Owning Organovo Holdings (NASDAQ:ONVO) And Trying To Stomach The 82% Share Price Drop - simplywall.st
Apparent Connections To A Convicted Stock Promoter: Another Chapter In The Organovo Saga (NASDAQ:VIVS) - Seeking Alpha
Vivosim Labs Inc Azioni (VIVS) Dati Finanziari
Non sono disponibili dati finanziari per Vivosim Labs Inc (VIVS). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.00%
0.54%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):